Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Secondary
1.6.1.1 Paid sources
1.6.1.2 Public sources
1.6.2 Primary
Chapter 2 Executive Summary
2.1 Antibiotic resistance industry 360º synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Disease trends
2.1.4 Pathogen trends
2.1.5 Drug class trends
2.1.6 Mechanism of action trends
2.1.7 Distribution channel trends
Chapter 3 Antibiotic Resistance Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of antibiotic resistant infections
3.2.1.2 Growing need for new antibiotic therapies
3.2.1.3 Increasing investment for research and development of novel antibiotics
3.2.1.4 Increasing global public health concern and awareness
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of therapeutics
3.2.2.2 Complex regulatory and development process
3.3 Growth potential analysis
3.3.1 By disease
3.3.2 By pathogen
3.3.3 By drug class
3.3.4 By mechanism of action
3.3.5 By distribution channel
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive positioning matrix, 2022
4.4 Strategic dashboard, 2022
Chapter 5 Antibiotic Resistance Market Estimates and Forecast, By Disease (USD Million)
5.1 Key trends, by disease
5.2 Complicated urinary tract infections
5.3 Complicated intra-abdominal infections
5.4 Bloodstream infection
5.5 Acute bacterial skin and skin-structure infection
5.6 Community-acquired bacterial pneumonia
5.7 Clostridium difficile infections
5.8 Hospital-acquired bacterial pneumonia
Chapter 6 Antibiotic Resistance Market Estimates and Forecast, By Pathogen (USD Million)
6.1 Key trends, by pathogen
6.2 E. coli
6.3 K. pneumoniae
6.4 P. aeruginosa
6.5 S. aureus
6.6 Baumannii
6.7 S. pneumoniae
6.8 H. influenzae
6.9 C. difficile
6.10 E. faecium
Chapter 7 Antibiotic Resistance Market Estimates and Forecast, By Drug Class (USD Million)
7.1 Key trends, by drug class
7.2 Oxazolidinones
7.3 Cephalosporin
7.4 Lipoglycopeptides
7.5 Combination therapies
7.6 Tetracyclines
7.7 Other drug classes
Chapter 8 Antibiotic Resistance Market Estimates and Forecast, By Mechanism of Action (USD Million)
8.1 Key trends, by mechanism of action
8.2 Cell wall synthesis inhibitors
8.3 Protein synthesis inhibitors
8.4 DNA synthesis inhibitors
8.5 RNA synthesis inhibitors
8.6 Other mechanism of actions
Chapter 9 Antibiotic Resistance Market Estimates and Forecast, By Distribution Channel (USD Million)
9.1 Key trends, by distribution channel
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
Chapter 10 Antibiotic Resistance Market Estimates and Forecast, By Region (USD Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Switzerland
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East & Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East & Africa
Chapter 11 Company Profiles
11.1 ACHAOGEN, INC.
11.2 Basilea Pharmaceutica Ltd.
11.3 MELINTA THERAPEUTICS
11.4 Tetraphase Pharmaceuticals, Inc.
11.5 Theravance Biopharma
11.6 WOCKHARDT
11.7 Entasis therapeutics
11.8 Paratek Pharmaceuticals, Inc.
11.9 Seres Therapeutics
11.10 AbbVie, Inc.
11.11 Merck & Co. Inc.
11.12 Pfizer Inc.
